AAA October 2014 – Page 23

Weekly corporate venturing deal net: 29 September-3 October 2014

Allakos, a US-based developer of antibodies to treat diseases that involve the excess production of inflammatory cells, received $10m on Tuesday from existing investors Novo Ventures and Roche Ventures, which act as the corporate venturing units of pharmaceutical companies Novo and Roche respectively, Alta Partners and RiverVest Venture Partners. The funding follows a $32m series… Continue reading Weekly corporate venturing deal net: 29 September-3 October 2014